ProPhase Historical Cash Flow
| PRPH Stock | USD 0.65 0.03 4.41% |
Analysis of ProPhase Labs cash flow over time is an excellent tool to project ProPhase Labs future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Total Cash From Financing Activities of 6 M or End Period Cash Flow of 2 M as it is a great indicator of ProPhase Labs ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining ProPhase Labs latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ProPhase Labs is a good buy for the upcoming year.
ProPhase |
About ProPhase Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in ProPhase balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which ProPhase's non-liquid assets can be easily converted into cash.
ProPhase Labs Cash Flow Chart
Add Fundamental
Change In Working Capital
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Depreciation
Depreciation indicates how much of ProPhase Labs value has been used up. For tax purposes ProPhase Labs can deduct the cost of the tangible assets it purchases as business expenses. However, ProPhase Labs must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Most accounts from ProPhase Labs' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into ProPhase Labs current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.As of now, ProPhase Labs' Change To Inventory is increasing as compared to previous years. The ProPhase Labs' current Stock Based Compensation is estimated to increase to about 3.7 M, while Change In Cash is forecasted to increase to (6.6 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation | 3.6M | 5.1M | 6.7M | 7.0M | Stock Based Compensation | 3.2M | 4.0M | 3.5M | 3.7M |
ProPhase Labs cash flow statement Correlations
Click cells to compare fundamentals
ProPhase Labs Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ProPhase Labs cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (1.1M) | 6.4M | 1.8M | 451K | (7.0M) | (6.6M) | |
| Free Cash Flow | (1.1M) | (4.3M) | (17.9M) | 24.6M | (14.5M) | (13.8M) | |
| Change In Working Capital | 1.1M | (608K) | (26.9M) | (4.3M) | (5.7M) | (5.4M) | |
| Begin Period Cash Flow | 1.6M | 434K | 6.8M | 8.7M | 9.1M | 7.3M | |
| Other Cashflows From Financing Activities | 5.5M | (10K) | (19.7M) | (14.5M) | 1.2M | 1.1M | |
| Other Non Cash Items | 40K | 118K | (311K) | 5.5M | 896K | 940.8K | |
| Capital Expenditures | 228K | 1.7M | 4.2M | 3.9M | 3.2M | 3.3M | |
| Total Cash From Operating Activities | (841K) | (2.6M) | (13.6M) | 28.6M | (11.3M) | (10.8M) | |
| Net Income | (3.1M) | (2.1M) | 6.3M | 18.5M | (16.8M) | (15.9M) | |
| Total Cash From Financing Activities | (5.8M) | 10.0M | 35.1M | (26.0M) | 5.8M | 6.0M | |
| End Period Cash Flow | 434K | 6.8M | 8.7M | 9.1M | 2.1M | 2.0M | |
| Change To Inventory | 444K | (1.5M) | (1.7M) | 702K | 135K | 141.8K | |
| Stock Based Compensation | 744K | 1.5M | 3.2M | 4.0M | 3.5M | 3.7M | |
| Depreciation | 398K | 458K | 3.6M | 5.1M | 6.7M | 7.0M | |
| Sale Purchase Of Stock | (16.3M) | 337K | (917K) | (9.6M) | (6.0M) | (6.3M) | |
| Change To Account Receivables | 936K | (1.0M) | (30.5M) | (4.5M) | 718K | 753.9K | |
| Change To Liabilities | (261K) | 3.3M | 5.1M | 481K | 553.2K | 447.2K | |
| Total Cashflows From Investing Activities | 11.9M | 5.5M | (1.0M) | (19.7M) | (17.7M) | (16.8M) | |
| Change Receivables | 3.8M | (1.0M) | 936K | (1.0M) | (1.2M) | (1.1M) | |
| Dividends Paid | 5.8M | 2.9M | 4.5M | 9.4M | 193K | 183.4K | |
| Cash And Cash Equivalents Changes | 2.7M | (1.6M) | (1.1M) | 11.6M | 13.3M | 14.0M | |
| Cash Flows Other Operating | (41.9M) | 148K | (8K) | (2.9M) | (2.6M) | (2.8M) | |
| Other Cashflows From Investing Activities | 5.8M | 3.9M | (700K) | 1.8M | 524K | 497.8K | |
| Change To Netincome | 796K | (318K) | 11.2M | 9.4M | 10.8M | 11.3M | |
| Investments | 5.8M | (720K) | (19.7M) | (2.1M) | (5.1M) | (5.4M) | |
| Change To Operating Activities | (198K) | (255K) | (1.4M) | 270K | 243K | 255.2K |
Currently Active Assets on Macroaxis
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.53) | Revenue Per Share 0.996 | Quarterly Revenue Growth (0.81) | Return On Assets (0.23) |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.